Tirzepatide

Explore Tirzepatide product variants and wholesale catalog information from Peptides of China.

Tirzepatide sits at the center of the fastest-growing segment in the china peptide export market. Dual-incretin research programs order chinese peptides like tirzepatide in volume, and the difference between a reliable supplier and a trader is visible in three places: specification documents, lot traceability, and consistency of delivery. Our platform exists to make all three checkable before ordering.

Tirzepatide Research Peptide | Wholesale Catalog | Peptides of China Tirzepatide Tirzepatide Research Peptide Tirzepatide is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. Sourcing is direct — no intermediaries. Public catalog minimum is $300 in goods per supplier. Eligible new customers may use one first-order trial without a monetary minimum; 5% off goods applies from $3,500 per supplier, excluding shipping. International shipping available.

Compound Profile

Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The molecule is based on a GIP sequence backbone with GLP-1 receptor pharmacophore elements incorporated at key positions, coupled with a C20 fatty diacid chain via a gamma-glutamic acid and mini-PEG linker for albumin binding and extended half-life (~5 days). This dual receptor activation profile distinguishes tirzepatide mechanistically from single-target GLP-1 agonists. Preclinical and clinical data generated through the SURPASS and SURMOUNT trial programs have established tirzepatide as one of the most studied peptides for metabolic research. In obesity models, tirzepatide produced greater body weight reductions than semaglutide in head-to-head rodent comparisons, attributed in part to GIP receptor-mediated effects on adipose tissue and thermogenesis. Mechanistic research continues to investigate how GIP receptor co-activation modulates the tolerability profile (nausea rates) compared to pure GLP-1 agonism, and how the two receptor pathways interact at hypothalamic, brainstem, and peripheral levels. Peptides of China supplies tirzepatide as a lyophilized powder in sealed vials at ≥98% purity verified by HPLC and mass spectrometry. Certificates of Analysis are available for each batch. All product is intended for laboratory research use only and is not approved for human administration.

Profile

Available Variants

Specification Highlights

Research Areas

Obesity & Body Composition Research Tirzepatide has demonstrated particularly pronounced effects on body weight in preclinical and clinical research. In the SURMOUNT-1 trial, weekly subcutaneous administration produced mean body weight reductions of up to 22.5% — exceeding results reported for semaglutide 2.4 mg in the STEP-1 trial under similar conditions. Preclinical rodent models suggest GIP receptor co-activation enhances lipid oxidation in adipocytes and may contribute to preferential fat mass reduction with preservation of lean tissue. These mechanistic questions remain active areas of investigation. Type 2 Diabetes & Beta-Cell Function SURPASS clinical trials documented statistically superior HbA1c reductions versus comparator compounds including semaglutide 1 mg, insulin degludec, and basal insulin combinations. Preclinical work in GIP receptor knockout mouse models confirms that the incremental glycaemic benefit of tirzepatide over GLP-1 monotherapy is dependent on intact GIP signalling. Beta-cell preservation and insulinoma cell proliferation assays are used to characterise the cytoprotective component of dual agonism. Non-Alcoholic Steatohepatitis (MASH/NASH) The SYNERGY-NASH trial investigated tirzepatide in biopsy-confirmed NASH, reporting histological resolution in a significantly higher proportion of participants versus placebo. Preclinical diet-induced NASH models (CDAA-HFD mice) show reductions in hepatic steatosis, lobular inflammation, and fibrosis staging. The mechanism is thought to involve GLP-1R–mediated hepatic lipid flux reduction and GIP-associated effects on adipose inflammation driving ectopic lipid deposition. Cardiovascular & Cardiometabolic Outcomes The SURPASS-CVOT (SURPASS-4) trial in subjects with T2D and high cardiovascular risk showed non-inferior and potentially superior trends in MACE versus insulin glargine. Preclinical ApoE⁻/⁻ and LDLr⁻/⁻ atherosclerosis mouse models demonstrate plaque-stabilising effects attributed to anti-inflammatory GLP-1R signalling. Research into tirzepatide’s effects on heart failure with preserved ejection fraction (HFpEF) is ongoing in the SUMMIT and SOLSTICE trials. ## Sourcing Tirzepatide From China

Tirzepatide is available through our platform as a china peptide sourced directly from an established Chinese manufacturer. Three points define how we handle it:

• Factory-direct, not trader-sourced. We confirm availability and specification with the manufacturer before the order is confirmed. There is no intermediary resale of unknown-origin vials in this catalog.
• Specification before shipment. The purity and concentration specification shown on this page is the manufacturer’s batch specification. Product-specific quality-control information travels with the order.
• Research-use discipline. Like every listing in our catalog, Tirzepatide is supplied for laboratory research use only, under strict research-use terms.

For buyers comparing chinese peptides suppliers, the practical test is whether the seller can name the manufacturer and show the batch documentation. We work the other way around: the manufacturer and the documentation are the offer. Browse the full catalog or see how sourcing works.